Article Text

Download PDFPDF

Original Article
GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects
  1. Konrad Platzer1,
  2. Hongjie Yuan2,3,
  3. Hannah Schütz4,
  4. Alexander Winschel4,
  5. Wenjuan Chen2,
  6. Chun Hu2,
  7. Hirofumi Kusumoto2,
  8. Henrike O Heyne1,
  9. Katherine L Helbig5,
  10. Sha Tang5,
  11. Marcia C Willing6,
  12. Brad T Tinkle7,
  13. Darius J Adams8,
  14. Christel Depienne9,10,11,12,
  15. Boris Keren9,10,
  16. Cyril Mignot10,
  17. Eirik Frengen13,
  18. Petter Strømme14,
  19. Saskia Biskup15,
  20. Dennis Döcker15,
  21. Tim M Strom16,
  22. Heather C Mefford17,
  23. Candace T Myers17,
  24. Alison M Muir17,
  25. Amy LaCroix17,
  26. Lynette Sadleir18,
  27. Ingrid E Scheffer19,
  28. Eva Brilstra20,
  29. Mieke M van Haelst20,
  30. Jasper J van der Smagt20,
  31. Levinus A Bok21,
  32. Rikke S Møller22,23,
  33. Uffe B Jensen24,
  34. John J Millichap25,
  35. Anne T Berg25,
  36. Ethan M Goldberg26,27,
  37. Isabelle De Bie28,
  38. Stephanie Fox28,
  39. Philippe Major29,
  40. Julie R Jones30,
  41. Elaine H Zackai31,
  42. Rami Abou Jamra1,32,
  43. Arndt Rolfs32,
  44. Richard J Leventer33,34,
  45. John A Lawson35,
  46. Tony Roscioli36,
  47. Floor E Jansen37,
  48. Emmanuelle Ranza38,
  49. Christian M Korff39,
  50. Anna-Elina Lehesjoki40,41,
  51. Carolina Courage40,41,
  52. Tarja Linnankivi42,
  53. Douglas R Smith43,
  54. Christine Stanley43,
  55. Mark Mintz44,
  56. Dianalee McKnight45,
  57. Amy Decker45,
  58. Wen-Hann Tan46,
  59. Mark A Tarnopolsky47,
  60. Lauren I Brady47,
  61. Markus Wolff48,
  62. Lutz Dondit49,
  63. Helio F Pedro50,
  64. Sarah E Parisotto50,
  65. Kelly L Jones51,
  66. Anup D Patel52,53,
  67. David N Franz54,
  68. Rena Vanzo55,
  69. Elysa Marco56,
  70. Judith D Ranells57,
  71. Nataliya Di Donato58,
  72. William B Dobyns59,60,61,
  73. Bodo Laube4,
  74. Stephen F Traynelis2,3,
  75. Johannes R Lemke1
  1. 1 Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany
  2. 2 Department of Pharmacology, Emory University School of Medicine, Rollins Research Center, Atlanta, Georgia, USA
  3. 3 Center for Functional Evaluation of Rare Variants (CFERV), Emory University School of Medicine, Atlanta, Georgia, USA
  4. 4 Department of Neurophysiology and Neurosensory Systems, Technical University Darmstadt, Darmstadt, Hessen, Germany
  5. 5 Division of Clinical Genomics, Ambry Genetics, Aliso Viejo, California, USA
  6. 6 Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA
  7. 7 Advocate Children’s Hospital, Park Ridge, Illinois, USA
  8. 8 Genetics and Metabolism, Goryeb Children’s Hospital, Atlantic Health System, Morristown, New Jersey, USA
  9. 9 INSERM, U 1127, Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR 7225, Institut du cerveau et de la moelle épinière (ICM), Paris, France
  10. 10 Département de Génétique, Centre de Référence des Déficiences Intellectuelles de Causes Rares, GRC UPMC “Déficiences Intellectuelles et Autisme”, Hôpital de la Pitié-Salpêtrière, Paris, France
  11. 11 UMR 7104/INSERM U964/Université de Strasbourg, Illkirch, France
  12. 12 Laboratoire de cytogénétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  13. 13 Department of Medical Genetics, Oslo University Hospitals and University of Oslo, Oslo, Norway
  14. 14 Department of Pediatrics, Oslo University Hospitals and University of Oslo, Oslo, Norway
  15. 15 Practice for Human Genetics and CeGaT GmbH, Tübingen, Germany
  16. 16 Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
  17. 17 Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle, Washington, USA
  18. 18 Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand
  19. 19 Department of Medicine, University of Melbourne, Austin Health and Royal Children’s Hospital, Melbourne, Victoria, Australia
  20. 20 Department of Genetics, Utrecht University Medical Center, Utrecht, The Netherlands
  21. 21 Department of Paediatrics, Màxima Medical Centre, Veldhoven, The Netherlands
  22. 22 The Danish Epilepsy Centre Filadelfia, Dianalund, Denmark
  23. 23 Institute for Regional Health Services, University of Southern Denmark, Odense, Denmark
  24. 24 Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark
  25. 25 Departments of Pediatrics, Epilepsy Center and Division of Neurology Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
  26. 26 Division of Neurology, The Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  27. 27 Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  28. 28 Department of Medical Genetics, Montreal Children’s Hospital, McGill University Health Center, Montreal, Canada
  29. 29 Department of Neurological Sciences, Université de Montréal, CHU Ste-Justine, Montreal, Canada
  30. 30 Greenwood Genetic Center, Greenwood, South Carolina, USA
  31. 31 Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
  32. 32 Centogene AG, Rostock, Germany
  33. 33 Department of Neurology, Royal Children’s Hospital, Melbourne, Victoria, Australia
  34. 34 Murdoch Childrens Research Institute and Department of Pediatrics, University of Melbourne, Melbourne, Victoria, Australia
  35. 35 Department of Neurology, Sydney Children’s Hospital, Sydney, New South Wales, Australia
  36. 36 Genome.One, Sydney, New South Wales, Australia
  37. 37 Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center, Utrecht, The Netherlands
  38. 38 Service of Genetic Medicine, University Hospitals of Geneva, Geneva, Switzerland
  39. 39 Department of Child and Adolescent, Neurology Unit, University Hospitals of Geneva, Geneva, Switzerland
  40. 40 The Folkhälsan Institute of Genetics, University of Helsinki, Helsinki, Finland
  41. 41 Research Programs Unit, Molecular Neurology and Neuroscience Center, University of Helsinki, Helsinki, Finland
  42. 42 Department of Pediatric Neurology, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  43. 43 Courtagen Life Sciences, Woburn, Massachusetts, USA
  44. 44 The Center for Neurological and Neurodevelopmental Health and the Clinical Research Center of New Jersey, Voorhees, New Jersey, USA
  45. 45 GeneDx, Gaithersburg, Maryland, USA
  46. 46 Division of Genetics and Genomics, Boston Children’s Hospital, Boston, Massachusetts, USA
  47. 47 Department of Pediatrics, McMaster University Children’s Hospital, Hamilton, Ontario, Canada
  48. 48 Department of Pediatric Neurology and Developmental Medicine, University Children’s Hospital, Tubingen, Germany
  49. 49 Department of Pediatric Neurology and Center for Developmental Medicine, Olgahospital Stuttgart, Stuttgart, Germany
  50. 50 Hackensack University Medical Center, Hackensack, New Jersey, USA
  51. 51 Department of Pediatrics, Division of Medical Genetics, University of Mississippi Medical Center, Jackson, Mississippi, USA
  52. 52 Nationwide Children’s Hospital, Columbus, Ohio, USA
  53. 53 The Ohio State University College of Medicine, Columbus, Ohio, USA
  54. 54 Department of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA
  55. 55 Lineagen, Inc., Salt Lake City, Utah, USA
  56. 56 Department of Neurology, University of San Francisco School of Medicine, San Francisco, California, USA
  57. 57 Department of Pediatrics, University of South Florida, Tampa, Florida, USA
  58. 58 Institute for Clinical Genetics, Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany
  59. 59 Center for Integrative Brain Research, Seattle Children’s Research Institute, Seattle, Washington, USA
  60. 60 Department of Pediatrics, University of Washington, Seattle, Washington, USA
  61. 61 Department of Neurology, University of Washington, Seattle, Washington, USA
  1. Correspondence to Dr Johannes R Lemke, Institute of Human Genetics, University of Leipzig, Leipzig, Germany; johannes.lemke{at}


Background We aimed for a comprehensive delineation of genetic, functional and phenotypic aspects of GRIN2B encephalopathy and explored potential prospects of personalised medicine.

Methods Data of 48 individuals with de novo GRIN2B variants were collected from several diagnostic and research cohorts, as well as from 43 patients from the literature. Functional consequences and response to memantine treatment were investigated in vitro and eventually translated into patient care.

Results Overall, de novo variants in 86 patients were classified as pathogenic/likely pathogenic. Patients presented with neurodevelopmental disorders and a spectrum of hypotonia, movement disorder, cortical visual impairment, cerebral volume loss and epilepsy. Six patients presented with a consistent malformation of cortical development (MCD) intermediate between tubulinopathies and polymicrogyria. Missense variants cluster in transmembrane segments and ligand-binding sites. Functional consequences of variants were diverse, revealing various potential gain-of-function and loss-of-function mechanisms and a retained sensitivity to the use-dependent blocker memantine. However, an objectifiable beneficial treatment response in the respective patients still remains to be demonstrated.

Conclusions In addition to previously known features of intellectual disability, epilepsy and autism, we found evidence that GRIN2B encephalopathy is also frequently associated with movement disorder, cortical visual impairment and MCD revealing novel phenotypic consequences of channelopathies.

  • epileptic encephalopathy
  • pathogenic GRIN2B mutations
  • channelopathy
  • clustering of missense variants
  • precision medicine
View Full Text

Statistics from


N-methyl-D-aspartate receptors (NMDAR) are ligand-gated ion channels expressed throughout the brain mediating excitatory neurotransmission. Signalling via NMDAR plays an important role in brain development, learning, memory and other higher cognitive functions. NMDAR are di-heterotetramers or triheterotetramers composed of two glycine-binding GluN1 (encoded by GRIN1) and two glutamate-binding GluN2 subunits (GRIN2A-D).1 Simultaneous binding of both agonists activates the NMDAR, which opens a cation-selective pore leading to an influx of Ca2+ and depolarisation. Compared with the ubiquitously expressed GluN1 subunit, the GluN2 subunits show specific spatiotemporal expression profiles throughout the central nervous system.2 GluN2B and GluN2D subunits are expressed prenatally, whereas expression of GluN2A and GluN2C significantly increases shortly after birth. Over time, postnatal expression of GluN2B becomes progressively restricted to the forebrain.

Pathogenic de novo variants in four genes encoding NMDAR subunits (GRIN1, GRIN2A, GRIN2B and GRIN2D) have been identified in patients with neurodevelopmental disorders comprising developmental delay (DD), intellectual disability (ID), autism spectrum disorders (ASD), epilepsy and epileptic encephalopathy, as well as movement disorders such as choreoathetosis or dystonia.3–13

To delineate the phenotypic spectrum of GRIN2B encephalopathy, we reviewed previously published and newly diagnosed patients with pathogenic/likely pathogenic de novo variants in GRIN2B. We evaluated the functional consequences of 16 variants in Xenopus laevis oocytes, investigated in vitro responses to memantine for six potential gain-of-function variants and aimed for translation of these results into personalised therapeutic approaches.

Materials and methods


We reviewed the clinical and genetic data of patients in whom GRIN2B de novo variants were detected within diagnostic or research settings focusing on neurodevelopmental disorders. Referring physicians provided detailed clinical information via a standardised clinical questionnaire. Molecular diagnostics were performed by targeted panel sequencing,14 whole exome sequencing (WES) or array comparative genomic hybridisation. All legal guardians provided informed written consent for genetic testing in accordance with the respective national ethics guidelines and with approval of the local ethics committees in the participating study centres.

Table 1

Heterozygous de novo missense variants and inframe deletions in GRIN2B

Variant classification

Variants in GRIN2B (NM_000834.3) were determined to be pathogenic, likely pathogenic or of unknown significance according to established guidelines of the American College of Medical Genetics (ACMG) (tables 1 and 2).15 All variants classified as (likely) pathogenic constitute de novo variants. The database of the Exome Aggregation Consortium (ExAC) served as the control population.16

Table 2

Heterozygous de novo truncating variants in GRIN2B

GRIN2B physiology

We used cDNA for wild-type (WT) human NMDA GluN1-1a (hereafter GluN1; NP_015566) and GluN2B subunits in pCI-neo (NP_000827.1).17 The mutant GluN2B constructs were generated by site-directed mutagenesis using the QuikChange protocol (Stratagene). Synthesis and injection of cRNA into Xenopus laevis oocytes (Ecocyte Inc.) and two-electrode voltage-clamp current (TEVC) recordings were performed at −40 mV and 23°C (unless otherwise stated), as previously described.18 Recording electrodes were filled with 0.3 M KCl for voltage electrode and 3 M KCl for the current electrode. The recording solution contained (in mM) 90 NaCl, 1 KCl, 10 HEPES, 0.5 BaCl2 and 0.01 EDTA (pH 7.4). The concentration-response curves were fitted with the following equations:

Response (%) = 100/(1 + (EC50 / (agonist)) nH ) Equation 1

Response (%) = (100 − minimum) / (1 + ((antagonist) / IC50) nH ) + minimum Equation 2

where nH is the Hill slope, EC50 is the concentration of the agonist that produces a half-maximal effect, IC50 is the concentration of the antagonist that produces a half-maximal effect, and minimum is the degree of residual inhibition at a saturating concentration of the antagonist. The effects of co-application of increasing concentrations of memantine and maximally effective concentrations of glutamate (100 µM) and glycine (30 µM) on the response of NMDAR were determined using TEVC recordings from oocytes co-expressing GluN1 with the WT or the mutant GluN2B. The concentration-effect curves were recorded at a holding potential of −40 mV and fitted with equation 2.

Patient treatment

Patients were offered memantine treatment after functional confirmation of a gain-of-function variant retaining memantine sensitivity in vitro. In four patients, oral memantine treatment was initiated aiming for doses of 0.5–0.6 mg/kg body weight per day referring to the dosage of a treatment trial in GRIN2A encephalopathy.19 Patients were neurologically assessed prior and during memantine treatment. Individual treatment trials were approved by the local ethics boards of the participating centres.


We evaluated 48 novel and all 43 previously published individuals with de novo GRIN2B variants. Overall, variants in 86 out of these 91 individuals were classified as pathogenic/likely pathogenic. For 58 patients (39 novel and 19 published), detailed clinical data were available to comprehensively delineate the phenotypic spectrum of GRIN2B encephalopathy. The novel variant p.(Ser810Arg) was identified in monozygotic twin brothers with identical phenotype who were thus regarded as only one index case.

Phenotypic spectrum

All patients carrying a (likely) pathogenic GRIN2B variant presented with DD, ID and/or ASD (86/86; 100%, table 1, table 2, detailed phenotypic data in online supplementary table 3). The level of ID could be specified in 52 of 58 patients, with a majority displaying severe ID (31/52; 60%), whereas smaller proportions had moderate (13/52; 25%) or mild ID (8/52; 15%). Autistic features were seen in 28% of patients (16/58). At the time of data ascertainment, about half of the patients have had seizures (30/58; 52%), with a variable age of onset ranging from birth to 9 years and the frequency of seizures varying from multiple per day to a few seizures per year. Patients presented with generalised seizures (18/30; 60%, mostly tonic or tonic-clonic), focal seizures (14/30; 47%) and/or epileptic spasms (11/30; 37%). EEG patterns comprised hypsarrhythmia, focal, multifocal and/or generalised epileptiform activity. Follow-up data concerning seizure outcome were available for 22 patients, with one half becoming seizure-free (11/22; 50%) and the other half remaining refractory to therapy. No obvious treatment strategy using conventional antiepileptic drugs (AED) was associated with a higher likelihood of seizure freedom. At least 31 patients displayed hypotonia (31/58; 53%), which required tube feeding in five patients (5/31; 16%). Spasticity was documented in 14 patients (14/58; 24%). In addition, six patients presented with dystonic, dyskinetic or choreiform movement disorders (6/58; 10%). Four patients (4/58; 7%) showed signs of developmental regression, two of whom were temporary and one case had recurrent regression. Microcephaly was seen in multiple patients (11/58; 19%) and cortical visual impairment (CVI) was reported in four (4/58; 7%), three of whom also had a malformation of cortical development (MCD).

Supplementary Material

Supplementary file
Table 3

Summary of pharmacological data

Neuroimaging data

Neuroimaging was performed in 44 of 58 patients: six patients (6/44, 14%) showed a consistent MCD intermediate between typical polymicrogyria (PMG) and the cortical appearance of tubulinopathies, consisting of mixed large and small gyri separated by shallow sulci, a smooth grey-white border and little infolding (figure 1). These patients also had hypoplastic corpus callosum of varying degrees, enlarged and mildly dysplastic basal ganglia, hippocampal dysplasia with thick leaves and open hilus as well as enlarged tecta (figure 1A, E and M). One patient had no septum pellucidum (figure 1C). Generalised cerebral volume loss, compatible with cerebral atrophy, was described in four additional patients (4/44; 9%).

Figure 1

MRI of patients with malformation of cortical development. MRI scans of patients p.(Ala639Val) (A–D), p.(Ser810Arg) (E–H), p.(Ile655Phe) (I–L), p.(Ala636Val) (M–P), p.(Arg693Ser) (Q–T), p.(Ser810Asn) (U–X), and a normal control (AA-DD) showing T1-weighted mid-sagittal images (first column), T2-weighted axial images through the basal ganglia (second column) and higher lateral ventricles (third column), and T2-weighted coronal images through the hippocampus (fourth column). The mid-sagittal images are normal except for mildly low forehead in several subjects (A, I, U), although several are slightly off the midline. The lower axial images show relatively large and mildly dysplastic basal ganglia compared with normal (asterisks in B, (F, J, N, R and V)). All axial images (middle two rows) show a diffuse irregular gyral pattern with small gyri and limited intracortical microgyri (white arrows on the right side of images that point to the left hemispheres), an appearance intermediate between typical polymicrogyria and the cortical appearance of tubulinopathies. The coronal images show hippocampal dysplasia with thick leaves and open hilus, which varies from severe (D, H, X) to moderate (L, P).

Genetic spectrum

The 86 (likely) pathogenic variants in GRIN2B comprise 52 distinct missense variants. Variants cluster within or in very close proximity to the ligand-binding domains S1 and S2, as well as transmembrane domains M1–M4 (figure 2A, table 1). The only variant escaping this clustering pattern is p.(Ile150Val) in the amino-terminal domain (ATD). Although most variants were unique, five variants occurred multiple times: p.(Arg540His), p.(Gly689Ser), p.(Arg696His), p.(Ile751Thr) and p.(Gly820Ala). The 21 distinct pathogenic variants presumably leading to truncation/haploinsufficiency comprised nonsense and frameshift variants (n=11), splice site variants (n=3), chromosomal rearrangements (n=3) as well as gross deletions encompassing only GRIN2B (n=4) (figure 2B, table 2). According to the ACMG criteria, five de novo variants were classified as variants of unknown significance (see online Supplement 2).15

Supplementary Material

Supplementary file
Figure 2

De novo variants in GRIN2B. (A) Clustering of (likely) pathogenic missense variants in GRIN2B. All but one of the (likely) pathogenic missense variants cluster in the ligand-binding or transmembrane domains of GluN2B, which are regions with little to no benign missense variation in the control population. The de novo missense p.(Arg1111His) and the inframe deletion p.(Lys976del) in the CTD were classified as VUS. (B) Location of pathogenic truncating variants in GRIN2B. The recurrent variant c.99dupC, p.(Ser34Glnfs*25) listed in ExAC is part of a homopolymer stretch of seven recurrent C nucleotides suggesting a technical artefact. Variants classified as VUS establish a premature termination codon in the last exon of GRIN2B, including a de novo truncating variant in a control individual p.(Arg1099Alafs*51).38 Red bars indicate pathogenic/likely pathogenic de novo variants. Blue bars indicate de novo VUS. Grey bars indicate single nucleotide variants (SNV) listed in one ExAC individual each. Black bars indicate SNV seen in more than one ExAC individual. ATD, amino-terminal domain; CTD, carboxy-terminal domain; ExAC, Exome Aggregation Consortium; M1–M4, transmembrane domain; S1, S2, ligand-binding domain; VUS, variants of unknown significance.

Frequency of GRIN2B encephalopathy

Several of our collaborators (RSM, DS, CS and SB) performed different diagnostic panel sequencing approaches in 3136 independent epilepsy patients revealing seven (likely) pathogenic GRIN2B variants and a diagnostic frequency of 0.22%. Three diagnostic WES trio cohorts reported 8051 patients with neurodevelopmental disorders (defined as human phenotype ontology terms (1) abnormality of the nervous system, (2) multiple congenital anomalies, (3) seizures or (4) ASD.20–22 Overall, 15 pathogenic/likely pathogenic GRIN2B variants (14 missense, 1 frameshift) were identified, equalling a similar frequency of 0.19%. Expanding the data of the Deciphering Developmental Disorders Study,23 14 de novo missense variants in GRIN2B are significantly enriched (p value 2×10−17) in a combined cohort of WES trio data (n=8051) of patients with neurodevelopmental disorders (see online supplement 3). Among 209 independent individuals with PMG, we identified two patients with de novo GRIN2B variants.

Functional investigation

Seven of 17 variants evaluated showed small apparent currents (less than 15 nA for 1000 µM glutamate and 100 µM glycine) (see online supplementary table 1). Because it was unclear whether these small currents were agonist evoked, the properties of these variants could not be studied further. We assessed the pharmacological properties of NMDAR containing the remaining 10 GluN2B mutants. Three variants (p.(Ser541Arg), p.(Val558Ile), and p.(Ile655Phe)) increased glutamate EC50 values (ie, decreased glutamate potency) by 6.7-fold, 2.8-fold and 3.7-fold (table 3), indicating that higher concentrations of glutamate are needed to activate these receptors. The variant p.(Ser541Arg) increased glycine EC50 values by 2.9-fold compared with WT receptors. Three variants (p.(Ser810Arg), p.(Met818Thr), and p.(Ala819Thr)) decreased both the glutamate and glycine EC50 values (ie, increased glutamate and glycine potency) (table 3), allowing these mutant receptors to be activated by lower concentration of agonists, suggesting a potential gain-of-function, provided trafficking and other features of receptor function are unchanged.

Voltage-dependent inhibition by extracellular Mg2+ and negative modulation by extracellular protons are two important features of NMDAR function. The voltage-dependent potency of Mg2+ inhibition showed that p.(Gly611Val) and p.(Ile655Phe) increased the Mg2+ IC50 value from 25 µM for WT NMDAR to over 1000 µM and 220 µM for NMDAR containing GluN2B-Gly611Val and GluN2B-Ile655Phe, respectively (−60 mV holding potential; p<0.05, one-way analysis of variance) (table 3). Proton sensitivity was evaluated by comparing the current amplitude at two different extracellular pH values (6.8 vs. 7.6). Four mutant GluN2B subunits (p.(Ile655Phe), p.(Ser810Arg), p.(Met818Thr) and p.(Ala819Thr)) show significantly larger current response at pH 6.8 compared with pH 7.6 than WT receptors (table 3), suggesting that these variants significantly reduce tonic proton inhibition. This could result in more current flowing through the channel when the receptor is bound by agonists. Taken together, these data suggest that three variants (p.(Ser810Arg), p.(Met818Thr) and p.(Ala819Thr)) are likely overactive under resting conditions† as a result of both the increased activation at low concentrations of agonists, reduced voltage-dependent Mg2+ block and reduced proton inhibition. The combination of these effects could potentially contribute to hyperexcitability and thus to patients’ epileptic phenotype. Further data are needed to determine how receptors with mixed functional changes (decreased agonist potency, decreased regulation by Mg2+ or protons) will alter, for example, charge transfer during synaptic transmission.

Evaluation of NMDAR antagonist memantine

The Food and Drug Administration-approved NMDAR antagonist memantine24 has been suggested to have anticonvulsant effects in some epilepsy animal models25 and was previously used off-label to effectively treat one patient with a gain-of-function GluN2A variant (p.(Leu812Met)).19 Thus, we evaluated its ability to inhibit six potential gain-of-function GluN2B variants (p.(Gly611Val), p.(Asn615Ile), p.(Val618Gly), p.(Ser810Arg), p.(Met818Thr) and p.(Ala819Thr))9 (see online supplementary figure 1 and supplementary table 2). The data indicated GluN2B-Gly611Val and GluN2B-Asn615Ile decreased memantine IC50 by 1.7-fold and 3-fold, respectively (ie, increased potency; 1.0 µM for p.(Gly611Val) and 0.44 µM for p.(Asn615Il)e compared with 1.7 µM of WT). The other four variants (p.(Val618Gly), p.(Ser810Arg), p.(Met818Thr) and p.(Ala819Thr)) increased the IC50 values (ie, decreased potency) compared with WT (see online supplementary figure 1 and supplementary table 2), suggesting that memantine can reduce NMDAR hyperactivity caused by these variants, although several mutants showed a reduced potency compared with WT receptors.

Targeted treatment with memantine

In four out of these six patients, we added memantine to the AED regimen (p.(Gly611Val), p.(Asn615Ile), p.(Val618Gly) and p.(Met818Thr)) (see online supplement 1). Parents and physicians initially observed beneficial effects such as improvements in awareness, behaviour and sleep. However, there were no changes in seizure frequencies and none of the potential benefits could be sufficiently objectivised. Long-term follow-up data were available in only one patient (p.(Val618Gly)) and did not suggest significant improvement.


We present the largest series of patients with (likely) pathogenic GRIN2B variants and provide a comprehensive review of the different aspects of GRIN2B encephalopathy. We strictly applied the ACMG criteria for variant classification to lessen the impact of potential biases caused by the heterogeneous collection of patients.

Phenotypic spectrum

In agreement with the known GRIN2B-associated features, our data confirm that all patients had DD and a majority developed severe ID, with autistic features in a quarter of patients. Half of the patients developed seizures with a broad heterogeneity with respect to age of onset, seizure semiology, EEG features and outcome. Expanding our previous observation, 37% of patients presented with epileptic spasms.9 Less frequent findings of GRIN2B encephalopathy include generalised cerebral volume loss, CVI, hyperkinetic movement disorders (dystonia, dyskinesia, chorea) and developmental regression. These features have been repeatedly observed in other GRIN-associated encephalopathies,4 5 10 12 19 26 27 suggesting a shared phenotypic spectrum, with differences likely reflecting variant class, location and effect in the various NMDAR subunits. However, we did not observe EEG patterns of continuous spikes and waves during sleep or centrotemporal spikes in our GRIN2B cohort, which appears to reflect a milder end of the GRIN spectrum that is so far predominantly associated with GRIN2A.28 As systematic genetic testing is more likely performed in patients with severe early-onset disorders, the mentioned frequencies of, for example, severe ID and epilepsy in GRIN2B encephalopathy are probably overestimated due to ascertainment bias.

Malformation of cortical development

Six patients presented with a consistent MCD intermediate between typical PMG and tubulinopathies. This has also been referred to as tubulinopathy-related dysgyria.29 Whereas tubulinopathies are classified as disorders of neuronal migration leading to cortical dysgenesis,30 PMG is considered to be due to postmigrational disruption of cortical development with fusion of cortical laminae.31 Knockdown of Grin2b in rat has been shown to disturb proper neuronal migration32 and glutamate has been implemented in its regulation.33 As GluN2B is predominantly expressed prenatally, disruption of neuronal migration seems to be the possible cause of GRIN2B-associated MCD. All six individuals had a very similar degree of severity and we did not observe less pronounced patterns of dysgyria in others. We can largely exclude the co-occurrence of, for example, known genetic tubulinopathies in all six cases, as individuals were screened by (trio)WES (n=4) or a panel targeting MCD genes (n=2). Other than in GRIN2B, we did not identify any other putatively causative variants in all six cases. Deficient ion channels are known to cause a plethora of human neurodevelopmental disorders, with the exception of abnormal cell migration. Despite the observation of six patients with pathogenic SCN1A variants who also had focal cortical dysplasia or bilateral periventricular nodular heterotopia,34 the identification of six unrelated individuals with (likely) pathogenic variants in GRIN2B and a consistent MCD expands the phenotypic spectrum and reveals novel phenotypic consequences of channelopathies.

Genetic spectrum

GRIN2B is a gene with a significantly reduced number of missense variants in controls, indicating a selective constraint.16 All (likely) pathogenic missense variants cluster within or in direct proximity to ligand-binding sites and transmembrane domains. These regions are largely spared by (likely) benign single nucleotide variants (SNV) in ExAC controls, suggesting that missense variants within these functionally important and conserved domains are only scarcely tolerated.35 36 In contrast, the ATD and carboxy-terminal domain (CTD), as well as two small segments within S1 and M1, are markedly enriched for (likely) benign SNV in controls. The likely pathogenic missense variant p.(Ile150Val) escapes this clustering pattern, as it is located within a stretch of ~300 bp that contains very few missense variants within the ATD. It remains unclear whether or not this variant alters subunit assembly, ligand-binding or allosteric regulation by extracellular Zn2+.1 2

The ratio of expected versus observed numbers of truncating variants of 33.9:0 in controls and the probability of loss-of-function intolerant score of 1.00 suggest that GRIN2B haploinsufficiency is most likely not tolerated.16 We observed seven truncating variants in the CTD establishing a premature termination codon in the last exon and therefore likely escaping nonsense-mediated mRNA decay and possibly not significantly altering protein function15 37: two de novo truncating variants in patients with ID,20 one de novo frameshift variant in a healthy control individual38 and four frameshift variants reported in ExAC. The ExAC-annotated frameshift variant c.99dupC, p.(Ser34Glnfs*25) occurring in 27 controls conflicts with the hypothesis of haploinsufficiency. However, this variant is part of a homopolymer stretch of seven recurrent C nucleotides, raising the suspicion of a technical artefact despite having been described as pathogenic de novo variant via different sequencing approaches in an individual with ASD.39

Genotype-phenotype correlations

MCD-associated variants are located in the transmembrane domain M3 (p.(Ala636Val), p.(Ala639Val) and p.(Ile655Phe)), in the ligand-binding domain S2 (p.(Arg693Ser)) or within the linker domain connecting S2 and M4 (p.(Ser810Arg) and p.(Ser810Asn)). Both missense variants at position 810 (p.(Ser810Arg) and p.(Ser810Asn)) were associated with MCD, whereas position 636 also showed two different (likely) pathogenic missense variants, with only p.(Ala636Val) being seen in MCD.40 Thus, the specific functional mechanisms mediating MCD still remain to be elucidated. In contrast to our previous hypothesis,9 we did not find a significant correlation between variant class (missense vs truncation) and occurrence of seizures (Fisher’s exact test, p=0.1187). However, there was a significant correlation between variant class and intellectual outcome (mild-moderate vs severe ID) (Fisher’s exact test, p=0.0079), with truncation carriers tending to present with mild or moderate instead of severe ID.

Functional investigation

We evaluated several different aspects of receptor function, as it is possible that variants could have opposing effects on receptor activity (eg, Ile655Phe). We found that several other variants (Ser810Arg, Met818Thr, Ala819Thr) showed multiple differences in their properties that each enhanced NMDAR function, suggesting a potential gain-of-function of NMDAR assuming there is no change in the fraction of receptors that reach the cell surface or synapse. Such functional changes could lead to excitotoxic cell death, circuit rewiring, changes in neuronal migration or persistent increases in excitatory synaptic and non-synaptic drive through surface receptors. Thus there are multiple ways these variant receptors could contribute to clinical symptoms. Extensive functional analyses of rare variants in the GluN2B agonist binding domain recently showed the multifaceted and sometimes conflicting consequences that these variants can have on NMDAR activity.36

Targeted treatment with memantine

Initial subjective improvements in awareness, behaviour and sleep could not be sufficiently objectivised, and seizure frequencies showed no significant changes. In three cases, the missense variant led to significant loss of Mg2+ block engaging a different mechanism compared with the multiple means by which channel function was enhanced in a patient with p.(Leu812Met) in GRIN2A, which responded favourably to memantine treatment.19 In comparison, the variant of the fourth individual (p.(Met818Thr)) displayed similarities with respect to, for example, the increased glycine and glutamate potency of the NMDAR; however this does not hold true for patients’ treatment response to memantine. At present, it remains entirely unclear whether memantine is effective at all in this patient population and what factors (eg, variant location, mechanism of gain-of-function, patient age, memantine dose, differences in blood and brain concentrations) might influence memantine treatment response. Although some variants retain sensitivity to channel blockers like memantine in vitro, translating these potential benefits into patient care still remains elusive. Options for personalised therapy in GRIN2B encephalopathy still require more systematic and thorough evidence best through double-blinded prospective trials with a homogeneous patient population in terms of variant class.


Given the frequency of about 0.2% among individuals with neurodevelopmental disorders and/or childhood-onset epilepsy, GRIN2B encephalopathy appears to be a recurrent and distinct diagnosis. Our observations of novel features expand the phenotypic spectrum and suggest novel consequences of channelopathies resulting in disturbed neuronal migration. We found phenotypic similarities and a marked clustering of missense variants in ligand-binding and transmembrane domains paralleling other GRIN-associated disorders. Despite the limited conclusions regarding treatment with memantine in four patients with potential gain-of-function variants, the diverse functional consequences of (likely) pathogenic variants possibly enable future personalised therapeutic approaches in patients with GRIN2B encephalopathy.

Web resource


We thank the patients and their families for their participation and support of this study. We thank Lisa Ewans, Michael F Buckley, Asbjørn Holmgren and Doriana Misceo for technical support.


View Abstract


  • Contributors KP, HOY, BIL, SFT, JRL conceived the project. KP, KLH, ST, MCW, BTT, DJA, CD, BK, CM, EF, SB, DD, TMS, HCM, CTM, AMM, AL, LS, IES, EB, LAB, RSM, UBJ, JJM, ATB, EMG, IDB, SF, PM, JRJ, EHZ, RAJ, AR, RJL, JL, TR, FEJ, ER, CMK, MMvH, JJvdS, AEL, CC, TL, DRS, CS, MM, DM, AD, WHT, MAT, BIL, MW, LD, SEP, KLJ, ADP, DNF, RV, EM, JDR, ND, WBD, SFT, JRL recruited and phenotyped patients. HY, HS, AW, WC, CH, HK, BIL, SFT performed in vitro experiments. KP, HY, HS, AW, WC, CH, HK, HOH, ND, WBD, BL, SFT, JRL performed data analysis and statistics. KP, HY, SFT, JRL wrote the manuscript. All authors edited the manuscript.

  • Funding Funding for the project was provided by the Eunice Kennedy Shriver National Institute of Child Health & Human Development (R01HD082373 to HY), by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454 (to HY), and by the National Institute of Neurological Disorders and Stroke (NS036654, R01NS065371 and R24NS092989 to SFT). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

    Additional funding was received from the Australian NHMRC (512123 to TR), NIH NINDS training grant (K12 NS049453 to EMG), Cure Kids NZ to LS and the SNSF Early Postdoc fellowship (P2SKP3_164945 to CC).

    Funding for the DECIPHER project was provided by the Wellcome Trust.

  • Competing interests SFT is a consultant of Janssen Pharmaceuticals, Inc., Pfizer Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, and co-founder of NeurOp Inc.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement This study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from and via email from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.